3Ladhani S. Understanding the mechanism of action of the exfohative toxins of staphylococcus aureus. Immun and Med Microbiol 2003; 39 (2) :181 - 189.
4Patel GK, Finlay AY. Staphylococcal scalded skin syndrome: Diagnosis and management. Am J Clin Dermatol 2003;4(3) - 165 - 175.
5Kang JD, Park SD. Reclassification of staphylococcal scalded skin syndrome by clinical analysis of 25 cases. Korean J Dermatol 2004; 42(4) :398 - 405.
6Lina G, Gillet Y, Vandenesch F, et al. Toxin involvement in staphylococcal scalded skin syndrome. Clin Infect Dis 1997; 25: 1369- 1373.
7Habif TP. Clinical Dermatology: A color guide to diagnosis and therapy. 3rd ed. St. Louis: Mosby, 1996.256-257.
8Hanakawa Y, Schechter NM, Lin C, et al. Molecular mechanisms of blister formation in bullous impetigo and staphylococcal scalded skin syndrome[J]. J Clin Invest, 2002, 110(1): 53-60.
9Shirakata Y, Amagai M, Hanakawa Y, et al. Lack of mucosal involvement in pemphigus foliaceus may be due to low expression of desmoglein 1[J]. J Invest Dermatol, 1998, 110(1): 76-75.
10Anzai H, Stanley JR, Amagai M. Production of low titers of anti-desmoglein 1 IgG autoantibodies in some patients with staphylococcal scalded skin syndrome [J]. J Invest Dermatol, 2006, 126(9): 2139-2141.
